Plant Name: Morinda morindoides
Taxonomic Information:
Plant ID: NPO22304
Plant Latin Name: Morinda morindoides
Taxonomy Genus: Morinda
Taxonomy Family: Rubiaceae
Plant External Links:
NCBI TaxonomyDB:
659048
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPR35; | |
| NPSR1; | |
| RECQL; TDP1; GLO1; HPGD; ALOX12; AKR1B1; HSD17B2; HSD17B10; NOX4; APEX1; POLB; | |
| ACHE; | |
| TOP2A; | |
| TEK; INSR; AXL; MET; FLT3; CDK1; EGFR; PIM1; KDR; SRC; IGF1R; AURKB; CSNK2A1; NUAK1; | |
| CA2; CA12; CA14; CA7; | |
| TYR; | |
| AHR; | |
| SLC22A6; | |
| L3MBTL1; | |
| SMAD3; HSPA1A; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
| Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 1.446E-10 | 1.749E-07 | AKR1B1, ALOX12, AURKB, AXL, CDK1, CSNK2A1, EGFR, GLO1, HSPA1A, IGF1R, KDR, PIM1, SMAD3, SRC, TEK |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 3.845E-09 | 2.093E-06 | AURKB, AXL, CDK1, CSNK2A1, EGFR, FLT3, HSPA1A, IGF1R, INSR, KDR, MET, NUAK1, PIM1, RECQL, SRC, TEK, TOP2A |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.590E-08 | 1.064E-05 | CA12, CA14, CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 3.483E-08 | 1.331E-05 | AXL, EGFR, INSR, MET, NOX4, SRC, TEK |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 5.448E-08 | 1.825E-05 | EGFR, IGF1R, INSR, KDR, SRC |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 2.066E-07 | 4.687E-05 | AKR1B1, APEX1, AXL, CDK1, CYP1B1 |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 6.265E-07 | 1.268E-04 | AXL, CDK1, CSNK2A1, EGFR, FLT3 |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 7.957E-07 | 1.575E-04 | EGFR, INSR, KDR |
| MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 8.149E-07 | 1.584E-04 | ACHE, APEX1, CSNK2A1, EGFR, FLT3, IGF1R, INSR, KDR, L3MBTL1, PIM1, SMAD3, SRC |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.135E-06 | 2.094E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 2.345E-06 | 4.085E-04 | AKR1B1, ALOX12, APEX1, CYP1A1, CYP1A2, CYP1B1, HPGD, HSD17B10, HSD17B2, NOX4, TYR |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.460E-06 | 4.252E-04 | CA12, CA14, CA2, CA7 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.696E-06 | 4.623E-04 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 4.616E-06 | 7.500E-04 | APEX1, POLB |
| BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 6.075E-06 | 9.361E-04 | CDK1, EGFR, IGF1R, INSR |
| MF | GO:0005488; binding | GO:0020037; heme binding | 8.256E-06 | 1.215E-03 | CYP1A1, CYP1A2, CYP1B1, NOX4, SRC |
| MF | GO:0005488; binding | GO:0019838; growth factor binding | 8.904E-06 | 1.301E-03 | EGFR, IGF1R, INSR, KDR, TEK |
| BP | GO:0032502; developmental process | GO:0007568; aging | 1.003E-05 | 1.447E-03 | APEX1, AURKB, CDK1, CYP1A1, NOX4, POLB |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.237E-05 | 1.727E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.383E-05 | 1.870E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 1.402E-05 | 1.872E-03 | EGFR, INSR, KDR, NOX4, SMAD3, SRC |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.642E-05 | 2.143E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.642E-05 | 2.143E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0040007; growth | GO:0045927; positive regulation of growth | 1.758E-05 | 2.278E-03 | ALOX12, CDK1, CSNK2A1, EGFR, INSR, PIM1 |
| BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 2.138E-05 | 2.630E-03 | CDK1, EGFR, FLT3, INSR, NOX4, SRC |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 2.605E-05 | 3.066E-03 | ACHE, CSNK2A1, EGFR, FLT3, HPGD, IGF1R, KDR, L3MBTL1, MET, SLC22A6, SMAD3, TOP2A, TYR |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.762E-05 | 3.199E-03 | CYP1A1, CYP1A2 |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 3.222E-05 | 3.579E-03 | AHR, AXL, CSNK2A1, EGFR, SRC, TOP2A |
| MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 3.358E-05 | 3.693E-03 | AXL, IGF1R, INSR |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 3.441E-05 | 3.733E-03 | ACHE, EGFR, IGF1R, INSR |
| BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 3.725E-05 | 3.977E-03 | FLT3, SRC, TEK |
| CC | GO:0016020; membrane | GO:0045121; membrane raft | 3.836E-05 | 4.074E-03 | EGFR, INSR, KDR, SLC22A6, SRC, TEK |
| BP | GO:0002376; immune system process | GO:0030097; hemopoiesis | 4.123E-05 | 4.296E-03 | FLT3, KDR, L3MBTL1, TEK |
| BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 4.164E-05 | 4.317E-03 | ACHE, CDK1, CYP1A1, EGFR, SMAD3 |
| MF | Unclassified; | GO:0032403; protein complex binding | 4.251E-05 | 4.387E-03 | ACHE, APEX1, EGFR, FLT3, IGF1R, INSR, KDR, SMAD3, SRC |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 4.538E-05 | 4.617E-03 | AHR, CSNK2A1, KDR |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 4.999E-05 | 4.970E-03 | CA2, EGFR, HPGD, SLC22A6, TEK |
| BP | GO:0050896; response to stimulus | GO:0051591; response to cAMP | 5.548E-05 | 5.417E-03 | APEX1, NOX4, TEK, TYR |
| BP | GO:0009987; cellular process | GO:0051495; positive regulation of cytoskeleton organization | 6.256E-05 | 6.028E-03 | HSPA1A, MET, NOX4, SMAD3, TEK |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 6.492E-05 | 6.110E-03 | CA12, CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 6.566E-05 | 6.110E-03 | EGFR, KDR, NOX4, SRC, TEK |
| CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 6.537E-05 | 6.110E-03 | ACHE, AKR1B1, APEX1, EGFR, HSPA1A, NOX4, SRC, TYR |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 6.885E-05 | 6.353E-03 | ALOX12, HPGD |
| MF | Unclassified; | GO:0004872; receptor activity | 8.035E-05 | 7.229E-03 | AHR, AXL, EGFR, FLT3, GPR35, HPGD, IGF1R, INSR, KDR, MET, NPSR1, TEK |
| BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 8.489E-05 | 7.514E-03 | AKR1B1, APEX1, IGF1R, INSR, SRC |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 8.489E-05 | 7.514E-03 | CA2, CA7, KDR, NPSR1, SRC |
| BP | Unclassified; | GO:0006461; protein complex assembly | 9.026E-05 | 7.925E-03 | ACHE, CDK1, HSD17B10, HSPA1A, IGF1R, INSR, SLC22A6, SMAD3, SRC, TEK |
| BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 9.620E-05 | 8.285E-03 | EGFR, INSR, SMAD3 |
| BP | GO:0032501; multicellular organismal process | GO:0007435; salivary gland morphogenesis | 9.626E-05 | 8.285E-03 | EGFR, POLB |
| MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 9.626E-05 | 8.285E-03 | FLT3, KDR |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 1.727E-10 | 2.107E-08 | SMAD3, CSNK2A1, SRC, INSR, MET, EGFR, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 6.309E-08 | 2.565E-06 | INSR, HSD17B2, CYP1A1, CYP1B1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 2.597E-07 | 7.921E-06 | SRC, INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 1.032E-06 | 2.518E-05 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 3.919E-08 | 2.390E-06 | CA12, CA2, CA7, CA14 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 7.460E-06 | 1.300E-04 | INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 6.564E-06 | 1.300E-04 | CYP1A2, HSD17B2, CYP1A1, CYP1B1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 7.348E-05 | 8.150E-04 | INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 6.428E-05 | 7.842E-04 | SRC, KDR, MET, EGFR, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 6.279E-05 | 7.842E-04 | SRC, KDR, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 6.388E-05 | 7.842E-04 | INSR, TEK, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 1.720E-04 | 1.614E-03 | SMAD3, INSR, EGFR, IGF1R |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 8.060E-05 | 8.194E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 3.282E-04 | 2.860E-03 | INSR, HSPA1A, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 3.757E-04 | 2.993E-03 | FLT3, MET, EGFR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.925E-04 | 2.993E-03 | SRC, MET, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 4.456E-04 | 3.198E-03 | MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.397E-03 | 7.412E-03 | SMAD3, FLT3, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 5.438E-04 | 3.492E-03 | HPGD, FLT3, MET, IGF1R |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 4.835E-04 | 3.277E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.174E-03 | 6.511E-03 | SRC, EGFR, HSPA1A |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 8.347E-04 | 4.849E-03 | SRC, CDK1, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 6.795E-04 | 4.145E-03 | CYP1A2, CYP1A1, CYP1B1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; SRC; |
| NA: NA | GIST | NA | FLT3; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TOP2A; MET; AURKB; IGF1R; KDR; FLT3; TEK; EGFR; SRC; |
| NA: NA | HIV infections | NA | AHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; SRC; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; INSR; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; AKR1B1; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; SRC; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; EGFR; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; EGFR; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| NA: NA | Edema | NA | CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; INSR; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; EGFR; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | INSR; AKR1B1; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; EGFR; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA2; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; EGFR; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; TYR; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; FLT3; ACHE; TEK; EGFR; SRC; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; TYR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; INSR; EGFR; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; SRC; |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
